RCS - Nuformix PLC - European Respiratory Society Congress Attendance

NuformixAnnouncement

25/09/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250925:nRSY7219Aa&default-theme=true

RNS Number : 7219A  Nuformix PLC  25 September 2025

REACH

 

25 September 2025

 

Nuformix plc

 

("Nuformix" or the "Company")

 

Attendance at European Respiratory Society Congress, Amsterdam 2025

 

Nuformix plc (LSE:NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, is pleased to
announce it will be attending the European Respiratory Society ("ERS")
Congress commencing from 28 September 2025 in Amsterdam.

 

At the ERS Congress the Company will share new insights relating to its NXP002
lead programme - an inhaled treatment for idiopathic pulmonary fibrosis and
related respiratory conditions. Following an in-depth pharmacology review,
leveraging human and AI-methodologies, the pathways associated with disease
progression in fibrotic diseases in which NXP002 has demonstrated both
activity and clinical translation have been assessed across multiple organs.

 

The resulting outputs allow clear demonstration of NXP002's potential to
regulate four specific pathways that drive fibrotic disease. This includes
core pathways, such as the TGF- ß pathway, but also evidences regulation of
the WNT/ß-catenin and NLRP3 pathways, which are emerging as key disease
progression pathways requiring suppression. The outputs also illustrate
consistent translation from cell-based studies to clinical studies across
multiple fibrotic organs, including the lung, in the resolution of extra
cellular matrix deposition.

 

The Company has summarised its findings in a new document 'NXP002 Pathway and
Translation Update' which is available via the following link
http://www.rns-pdf.londonstockexchange.com/rns/7219A_1-2025-9-24.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/7219A_1-2025-9-24.pdf)  and
will be published on the Company's website.

 

The Company continues to have ongoing discussions with potential development
partners and will further showcase NXP002 at the ERS Congress.

 

Dr Dan Gooding, Executive Director, Nuformix, said: "We are very much looking
forward to attending the ERS Congress in Amsterdam. We believe that inhalation
is now a validated and attractive treatment option for IPF and PPF. We also
believe that delivering improved treatments to patients requires regulation of
multiple disease pathways involved in fibrosis progression, given the
complexity of the underlying disease. Our recent analysis allows us to
evidence with new clarity the specific pathways NXP002 is supressing and how
this multi-pathway approach may enable improved treatment of these devastating
lung diseases, with the potential to restore tissue function supported by a
clinical evidence base.

 

"We await news on our US FDA orphan drug designation application and continue
discussions with potential licensing partners. We will provide further updates
in due course as appropriate."

 

Enquiries:

 

 Nuformix plc
 Dr Dan Gooding, Executive Director  Via IFC Advisory

 CMC Markets
 Douglas Crippen                     +44 (0) 20 3003 8632

 IFC Advisory Limited
 Tim Metcalfe                        +44 (0) 20 3934 6630

 Zach Cohen                          nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities.  Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

 

About IPF

 

IPF is a chronic lung disease characterised by progressive tissue scarring
that prevents proper lung function. It is a progressive, fatal, age-associated
lung disease affecting approximately three out of every one hundred thousand
people in Europe. IPF typically presents in adults 65 or older and is usually
fatal within two to five years after diagnosis.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUSSARVVUKUUR